企業を読み込み中
$0.75-3.3%11月13日 終値
2026年6月30日までの数値（2026年10月26日提出の6-Kより）
過去の推移
- 1W
- -20.5%
- 1M
- -51.9%
- 3M
- -72.0%
- 6M
- -91.3%
- 1Y
- -92.8%
$0.75-3.3%11月13日 終値
2026年6月30日までの数値（2026年10月26日提出の6-Kより）
企業自身の 6-K から。
“The first half of 2026 marked a period of profound structural execution and milestone achievement for SL Science. We successfully closed our business combination on June 12, and listed on the Nasdaq Global Market on June 15, supported by a concurrent $7.8 million PIPE financing. This capitalization provides the foundational strength required to advance our clinical programs. Concurrently, our deliberate pivot from direct retail to a B2B wholesale distribution model in Taiwan yielded immediate results. We drove a 23% increase in top-line revenue and expanded our gross margin to over 40% through enhanced volume predictability and optimized supplier pricing agreements,”
発表資料から逐語で引用し、書類が氏名のある人物に帰属させている場合にのみ表示します。
SL Science Holding Limited is a biomedical company specializing in developing innovative cellular and gene therapies. Established with a commitment to advancing regenerative medicine and cancer treatment, the Company hopes to utilize immune cell technologies to target cancer, thus potentially offering expansive medical applications for its products. With technologies such as Gamma Delta T cells targeting solid tumor indications including pancreatic and brain cancers, SL Science aims to create cellular therapies that the Company believes have the potential to advance the cell therapy and immuno-oncology sector within the broader biopharmaceutical industry.
発表資料の末尾に記載された、企業自身による説明です。
引用と会社概要は、SL Science Holding Ltd が 2026年10月26日 に提出した決算の 6-K からです。表は同社の四半期報告書に基づきます。 EDGAR で発表資料を読む 株価は分割と配当で調整済みです。
SL Science Holding Ltd の決算説明会の書き起こしはありません。